Overview

A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy

Status:
Recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
The goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy (DEE), aged 2 to 18 years.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Praxis Precision Medicines
Treatments:
Pramoxine